Coronado Biosciences to Present at the Jefferies 2013 Global Healthcare
BURLINGTON, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc.
(Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel
immunotherapy biologic agents for the treatment of autoimmune diseases and
cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and
CEO, will present at the Jefferies 2013 Global Healthcare Conference on
Monday, June 3, 2013, at 1:00 PM ET. The conference will be held at the Grand
Hyatt New York on June 3-6, 2013. A webcast of the presentation will be
available at www.coronadobiosciences.com on the Events & Webcasts page.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy
biologic agents. The company's two principal pharmaceutical product candidates
in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic
for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative
colitis and multiple sclerosis; and CNDO-109, a biologic that activates
natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML),
multiple myeloma and solid tumors. For more information, please visit
CONTACT: Lucy Lu, MD, Executive Vice President
& Chief Financial Officer
Coronado Biosciences, Inc.
Marcy Nanus, Vice President
The Trout Group, LLC.
Dian Griesel Inc.
Coronado Biosciences logo
Press spacebar to pause and continue. Press esc to stop.